<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Tuesday, TG Therapeutics, Inc. (TGTX) announced positive topline Phase 1 data for BRIUMVI in patients with myasthenia gravis, a chronic autoimmune neuromuscular disease.</p><p>At Week 24, 82 per cent of patients who received BRIUMVI achieved the Minimal Clinically Important Difference in MG-ADL, with a mean improvement of 4.6 points.</p><p>Moreover, consistent reductions from baseline were observed across all myasthenia gravis outcome measures over time following treatment with subcutaneous BRIUMVI</p><p>Also, the company announced the commencement of Phase 2 trial to evaluate the efficacy and safety of BRIUMVI in maintaining clinical response in patients with myasthenia gravis who initially respond to treatment with the FcRn inhibitor efgartigimod.</p><p>The trial, expected to enroll about 120 patients, will initially utilize the approved intravenous BRIUMVI dosing regimen, with subcutaneous BRIUMVI administration to be incorporated at a later stage following completion of pharmacokinetic bridging studies currently underway in multiple sclerosis.</p><p>Following completion of the randomized period, all patients will be eligible to enter a 72-week open-label extension evaluating treatment with BRIUMVI.</p><p>Currently, TGTX is trading at $42.51, up 3.81 percent on the Nasdaq. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

TGTX

<p>TG Therapeutics announced positive Phase 1 data for BRIUMVI in myasthenia gravis patients, with 82% achieving clinical improvement at Week 24. The company initiated a Phase 2 trial to evaluate BRIUMVI's efficacy in maintaining response after initial treatment with efgartigimod. Following the announcement, TGTX stock rose 3.81% to $42.51.</p>

TG Therapeutics Announces Positive Data From BRIUMVI Study, Initiates Phase 2 Trial; Stock Gains